Imperial College London, School of Public Health, London, UK.
Division of Cardiology, Emory University School of Medicine, Georgia, Atlanta, USA.
Catheter Cardiovasc Interv. 2023 Oct;102(4):751-760. doi: 10.1002/ccd.30806. Epub 2023 Aug 14.
Transcatheter edge-to-edge repair (TEER) may have potential benefits in the treatment of atrial functional mitral regurgitation (AFMR), but robust evidence is currently lacking. We conducted a systematic review and meta-analysis to investigate the clinical outcomes of TEER for AFMR, including comparisons to ventricular functional MR (VFMR).
MEDLINE and EMBASE were searched through January 2023 to identify studies eligible for analysis. The primary outcome was postprocedural MR severity. Postprocedural New York Heart Association (NYHA) functional class classification and all-cause mortality were also evaluated. Outcomes were stratified into short term (postprocedure to 6 months) and long term (6 months to 2 years).
A total of eight observational studies met the inclusion criteria, enrolling 539 AFMR and 3486 VFMR patients. Postprocedural MR grade ≤2 in the AFMR group was observed in 93.7% (454/491 patients; 95% confidence interval (CI), 91.1%-96.2%, I = 24.3%) and 97.1% (89/93 patients; 95% CI, 92.9%-100%, I = 26.4%) in short- and long-term follow-up, respectively. There was no difference in the rates of postprocedural MR grade ≤2 between AFMR and VFMR either in short-term (risk ratio [RR], 1.00 [95% CI, 0.95-1.06]; p = 0.90; I = 53%) or long-term follow-up (RR, 1.08 [95% CI, 0.89-1.32]; p = 0.44; I = 22%). Similarly, no difference was observed between AFMR and VFMR in the rates of postprocedural NYHA class ≤2 or all-cause mortality.
TEER provides similar clinical outcomes for AFMR and VFMR. A high rate of MR grade ≤2 was observed in patients at both short- and long-term follow-ups. Further prospective studies with TEER versus medical therapy and/or rhythm control for AFMR are warranted.
经导管缘对缘修复(TEER)在治疗心房功能性二尖瓣反流(AFMR)方面可能具有潜在益处,但目前缺乏有力的证据。我们进行了一项系统评价和荟萃分析,以调查 TEER 治疗 AFMR 的临床结果,包括与心室功能性 MR(VFMR)的比较。
通过 MEDLINE 和 EMBASE 检索 2023 年 1 月之前的研究,以确定符合分析标准的研究。主要结局为术后 MR 严重程度。还评估了术后纽约心脏协会(NYHA)功能分类和全因死亡率。结果分为短期(术后至 6 个月)和长期(6 个月至 2 年)。
共有 8 项观察性研究符合纳入标准,共纳入 539 例 AFMR 和 3486 例 VFMR 患者。在短期和长期随访中,AFMR 组的术后 MR 分级≤2 分别为 93.7%(454/491 例;95%置信区间[CI],91.1%-96.2%,I 2 =24.3%)和 97.1%(89/93 例;95%CI,92.9%-100%,I 2 =26.4%)。在短期(风险比[RR],1.00[95%CI,0.95-1.06];p=0.90;I 2 =53%)或长期随访(RR,1.08[95%CI,0.89-1.32];p=0.44;I 2 =22%)中,AFMR 和 VFMR 之间术后 MR 分级≤2 的发生率均无差异。同样,在术后 NYHA 分级≤2 或全因死亡率方面,AFMR 和 VFMR 之间也无差异。
TEER 为 AFMR 和 VFMR 提供了相似的临床结果。在短期和长期随访中,均观察到较高的 MR 分级≤2 发生率。需要进一步进行前瞻性研究,比较 TEER 与 AFMR 的药物治疗和/或节律控制。